(Q37734197)

22 August 2017

1 reference

title

Systemic therapy for advanced hepatocellular carcinoma: past, present, and future (English)

1 reference

22 August 2017

main subject

hepatocellular carcinoma

1 reference

1 reference

Jennifer L Giglia

1

1 reference

22 August 2017

Scott J Antonia

2

1 reference

22 August 2017

Lawrence B Berk

3

1 reference

22 August 2017

Salvador Bruno

4

1 reference

22 August 2017

Sophie Dessureault

5

1 reference

22 August 2017

Steven E Finkelstein

6

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

17

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

120-129

1 reference

Primary liver cancer: worldwide incidence and trends

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Treatment of hepatocellular carcinoma with adriamycin.Preliminary communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

5-Fluorouracil in hepatocellular carcinoma.Report of twenty-one cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

A phase II study of irinotecan in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Selection of patients with hepatocellular carcinoma for sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Assumptions of the tumor 'escape' hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Dendritic cell-based vaccination in solid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700207

10.1177/107327481001700207

21 January 2018

Identifiers

DOI

0 references

1 reference